Top Series B AI companies

Companies building AI products, foundation models, and applied ML platforms. Filtered to companies whose latest disclosed round is Series B.

Hiring from these companies? Find the people who work there.

Change the role to whoever you are hiring, or narrow the list below. 500 free credits on sign-up, no card needed.

Built from a search like: “Top Series B AI companies”

Ranked by current headcount across Series B AI companies. Refreshed monthly.

1
Foundation Medicine· Boston, Massachusetts, United States
Foundation Medicine is a global, patient-focused precision medicine company delivering high-quality, transformative diagnostic solutions in cancer and other diseases. We provide tests and solutions to transform care throughout a patient’s experience, from defining a diagnosis to determining the appropriate treatment to ongoing monitoring. We help accelerate the development of new personalized therapies by leveraging our vast knowledge of precision medicine, real world data and AI-powered tools, expanding the information our diagnostic solutions provide to enable improved outcomes for patients. Every day, we are inspired to think differently to transform the lives of people living with cancer and other diseases. For more information, visit us at www.FoundationMedicine.com.Community Guidelines: bit.ly/FMICommunityGuidelines
- Series B
- 1.8k employees
- Founded 2010
2
Novogene· Beijing, Beijing, China
Novogene specializes in the application of advanced molecular biotechnology and high-performance computing in the research fields of life science and human health. Established in March 2011, Novogene strives to become a global leader in providing genetic science services and technology products. Novogene has set up operations and laboratories in the United States, the United Kingdom, Netherlands, Germany, as well as in China, Singapore and Japan.Novogene currently consists of a comprehensive, and interdisciplinary team, the majority of which hold advanced degrees from top universities in China and abroad. The company has established high-flux, large-scale gene sequencing and high-performance computing platforms, which support effectively the demands of life science research and medical health for big data analysis and storage. Novogene has served over 7,300 global customers, covering 90 countries and regions across 6 continents. We have cooperated extensively with many academic institutions and completed several advanced-level, international genomics research projects. By 2023, Novogene has co-published and/or been acknowledged in more than 22,850 articles in Science Citation Index, with an accumulative impact factor of more than 148,250. Our partners are worldwide and include more than 4,200 scientfic research institutions and universities, more than 680 hospitals and over 2,400 pharmaceutical and agricultural enterprises. Currently, Novogene has obtained 356 software copyrights and 66 patents. As the leader in genome sequencing, Novogene’s business spans across scientific research for life science, medical research and technology services, storage-building sequencing platform services, gene sequencing, mass spectrometry and bio-information technology support for global research, scientific research institutions, hospitals, pharmaceutical R&D enterprises and agricultural enterprises.
- Series B
- 741 employees
- Founded 2011
3
Sinocare Inc.· CHANGSHA, Hunan, China
As a high-tech company, Sinocare Inc. has been dedicating itself to bio-sensor technology research & development, manufacturing and marketing of POCT products since its establishment in Aug,2002. Sinocare focuses intensively and extensively on the R&D of products and innovation of technology, casting our look into the future, to deliver significant benefits for people pursuing healthy living.In March, 2012, Sinocare Inc. was listed on Shenzhen Stock Exchange, abbreviated as "Sinocare" with stock code 300298. We passed ISO13485 and our products were certified by EU CE.The company's Sinocare glucometer series and its test strips has won an universal recognition from a large number of consumers thanks to its accuracy, simplicity and affordability. The product is not only popular in China, but also exports in large scale. Observing the values of “equality, honesty, innovation and excellence”, Sinocare conducts continuous innovation and establishes "portable laboratory" based on POCT product. The company aims at providing quality product and service for China’s chronic disease management, help chronic disease patients improve living quality and reduce the burden of social medical care system.
- Series B
- 590 employees
- Founded 2002
Live search
This list is a starting point
I can run a natural-language search across LinkedIn, GitHub, and the open web. Fire one of these, or edit the box up top to match exactly who you're after.
- Series B AI companies in San FranciscoRun
- Series B AI companies hiringRun
500 free credits on sign-up, no card needed.
4
INCOG BioPharma Services· Fishers, Indiana, United States
Our services support injectable drug products, including technical transfer, analytical method development and validation, process scale up, and formulation & filling of vials, syringes and cartridges. In addition, we offer customized packaging services to include labeling, device assembly, auto injector assembly, cartoning, final packaging and integrated storage solutions at various temperature conditions.
- Series B
- 446 employees
- Founded 2020
5
Isomorphic Labs· London, England, United Kingdom
Isomorphic Labs is here to advance human health by building on and beyond the Nobel-winning AlphaFold system. Our interdisciplinary team has developed a unified, state-of-the-art drug design engine that will transform how we design new drugs, and ultimately change the way medicine will help and heal people. Every day, and with each new breakthrough, we’re getting closer to achieving our ambitious mission to one day solve all disease
- Series B
- 434 employees
- Founded 2021

6
Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes· Taiwan, Province of China
The main objectives are as follows:‧Develop novel biotechnology and pharmaceutical R&D. Discover new drugs for local-prevalent diseases and other diseases based on medical needs. ‧Coordinate domestic collaborative efforts in drug R&D to better utilize the available resources. ‧Transfer drug candidates to pharmaceutical companies to improve biotechnology and pharmaceutical industries in Taiwan.
- Series B
- 266 employees
- Founded 2019
7
hVIVO· Canary Wharf, All Saints, West India Quay, Westferry, Heron Quays, South Quay, Island Gardens, East India Dock Road, East India, London Arena, Coldharbour, Limehouse, Millwall, Mudchute, Cubitt Town, Blackwall, Poplar, England, United Kingdom
hVIVO plc (Ticker: HVO) is a science‐led early‐phase drug development company purpose‐built to meet the growing complexity of modern clinical research. The Company operates an integrated early‐phase ecosystem that combines specialist clinical sites, advanced virology and immunology laboratories, human challenge expertise, and early drug development consulting. This unified model enables sponsors to generate rigorous, decision‐ready human data earlier in development, reducing uncertainty and accelerating progression through Phase I and II trials.With industry‐leading capabilities in respiratory and infectious disease, alongside expanding expertise in cardiometabolic and other high‐growth therapeutic areas, hVIVO supports a diverse global client base that includes seven of the world’s ten largest biopharmaceutical companies. Its London quarantine facilities are the largest purpose‐built human challenge units in the world, complemented by additional early‐phase clinical capacity in Germany and a specialist consulting team providing strategic, regulatory, and biometry expertise.The Company’s integrated approach delivers a seamless pathway from preclinical planning through early proof‐of‐concept, supported by continuous patient recruitment through FluCamp and a network of outpatient clinical sites for Phase II and III studies. By unifying scientific insight, operational control, and advanced laboratory capabilities, hVIVO provides sponsors with the clarity, speed, and reliability required to advance new medicines with confidence.
- Series B
- 246 employees
- Founded 1989
8
Alloyed· Begbroke, Bletchingdon, Hampton Poyle, Islip, Charlton-on-Otmoor, Yarnton, Tackley, Oddington, Shipton-on-Cherwell, Kirtlington, Water Eaton, Fencott, Nethercott, Kidlington, Thrupp, Murcott, England, United Kingdom
Alloyed (formerly OxMet Technologies) delivers next generation performance for metal components through its unique stack of technologies.
- Series B
- 228 employees
- Founded 2017
9
Kardigan· Princeton, New Jersey, United States
Kardigan is a patient-driven heart health company that is modernizing cardiovascular drug development to deliver medicines that move patients beyond symptom management to functional cures. By matching critical disease drivers with treatment responders identified in clinical trials, Kardigan is developing a portfolio of medicines that modify the underlying cardiovascular disease pathophysiology to get patients closer to the cures they deserve. Kardigan has significant East and West Coast operations and focus. For more information about Kardigan, please visit kardigan.bio. If you are interested in joining our passionate and driven team with deep cardiovascular, biotechnology and operational expertise, please visit kardigan.bio or the careers tab of this page.
- Series B
- 227 employees
- Founded 2023
10
QuEra Computing Inc.· Brighton, Massachusetts, United States
Quantum computing is moving from "one day" to "day one." QuEra Computing is leading that transition.Founded in 2018 on breakthrough research from Harvard and MIT, QuEra builds neutral-atom quantum computers using a unique multi-zone architecture. The result: reconfigurable qubit connectivity, room-temperature operation, and a scalable path to fault-tolerant quantum computing, with dozens logical qubits already demonstrated.QuEra systems are operational today. The company delivered a 260-qubit quantum computer to Japan's AIST integrated with one of the world's most powerful supercomputers, earned selection for DARPA's Quantum Benchmarks Initiative, and offers its Aquila quantum computer on Amazon Braket. Its Gemini gate-based system extends these capabilities for enterprise and research applications.Backed by $230M from Google, NVIDIA, SoftBank, and others, QuEra partners with Dell Technologies, NVIDIA, Deloitte, and a 29-member Quantum Alliance. Headquartered in Boston with operations in Japan and the UK. Visit quera.com to learn more.
- Series B
- 208 employees
- Founded 2018

Reveal 517 more·500 free credits, no card

Find engineers and founders at Series B AI companies

Series B AI companies are some of the most active hirers in the market. The list above ranks the largest AI companies whose latest disclosed round is Series B, by current headcount, drawn from public LinkedIn and Crunchbase records. Across 522 matching companies, you’ll find senior engineers, founding designers, and operators worth tracking.

Companies at this stage in AI share a profile: a working product, fresh capital, and a hiring plan that wants senior people yesterday. Looking at headcount, last round, and HQ side by side gives you a quick read on where AI talent is concentrating right now.

Refolk converts this list into a search. Ask for “Series B AI founders hiring senior engineers” or “design leads at Series B AI companies” and Refolk returns a fresh ranked shortlist with the sources behind each match.

How this list is built

Refolk pulled AI companies whose latest disclosed funding round is Series B from public LinkedIn and Crunchbase records, ranked them by current employee count, and kept those with at least 5 employees. The list refreshes monthly.

Last refreshed: Tue, 20 Oct 2026 17:46:03 GMT

Search this list

Need an even more specific search?

Refolk runs natural-language searches across LinkedIn, GitHub, and the open web. Try one of these:

500 free credits on sign-up, no card needed.

Related lists

See all company lists.

Or zoom out

Slice this list a different way

Common questions

How is this ranking built?

The list draws on the public company graph - headcount and growth signals, funding history, and recency. The criteria chips at the top show exactly which filters produced it, and the methodology section explains the ranking.

How fresh is the data?

The underlying index updates continuously and this ranking is rebuilt monthly. Last refreshed: Tue, 20 Oct 2026 17:46:03 GMT. For a list built against the index as it stands today, sign up and run the search live.

Can I get the full list of 522 companies?

Yes. This page shows the top of the ranking; sign up and I'll run the search live for the complete, current list. You start with 500 free credits, no card required.

Can I find the people inside these companies?

Yes. Ask in plain English - for example "engineering leaders at these companies who joined in the last year" - and I return the specific people, with context on each.

Try it on the search you came here for

Stop building boolean strings. Just describe the person.

Type one sentence. I plan the search, read GitHub, public LinkedIn and Crunchbase records, and the open web as it is right now, and hand back a ranked list with the reason next to every name.

01Describe them
One plain sentence. Role, city, stack, stage, whatever matters to you.
02I read the web live
GitHub, public LinkedIn and Crunchbase records, the open web. Not a database that went stale last quarter.
03You read the shortlist
Ranked, with the reasoning under every name. Open a profile, ask a follow-up, narrow it down.

No boolean, no filters, no seat to buy. One box.
Read at search time, so a profile updated yesterday counts today.
Every step visible as it runs, every name with its reason.

500 free credits on sign-up. No card, no demo call. See real searches.